Markets

Intersect ENT prices IPO at $11, the low end of the range

Intersect ENT, which sells absorbable nasal implants for post-surgical sinusitis relief, raised $55 million by offering 5.0 million shares at $11, the low end of the range of $11 to $13. Intersect ENT plans to list on the NASDAQ under the symbol XENT. Intersect ENT initially filed confidentially on 5/2/2014. J.P. Morgan and Piper Jaffray acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

XENT

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More